Immune Design Corp.

The clinical pipeline of lentivirus-based gene therapies for rare diseases contains at least 19 programs by 10 companies

Improved antivirals, antibodies, vaccines and possible cures enter the horizon

Plus: Mavilio, Loggia join Orchard and updates from PMV, Verseau, Apexigen, VectivBio, Protagonist and more

Recent and future BD will help drive Merck's innovation, while slower-growing businesses are headed for a new entity

With a management team stocked with ex-Medivation execs, Nuvation aims to develop a broad oncology pipeline

New commercial incentives could reward Merck for staying the course in infectious disease